+ All Categories
Home > Documents > The Evaluation Of Ischemia

The Evaluation Of Ischemia

Date post: 04-Jan-2016
Category:
Upload: lee-chan
View: 14 times
Download: 0 times
Share this document with a friend
Description:
The Evaluation Of Ischemia. Case. - PowerPoint PPT Presentation
52
The Evaluation Of Ischemia
Transcript
Page 1: The Evaluation Of Ischemia

The Evaluation Of Ischemia

Page 2: The Evaluation Of Ischemia

Case

• A 58 year old woman with diabetes and hypertension presents with symptoms of chronic chest pain. She reports that she can walk about 4 blocks at a moderate pace before developing squeezing chest pain, shortness of breath and diaphoresis that resolves with rest. An EKG in the office is normal.

Page 3: The Evaluation Of Ischemia

Case

• What is the best next step?– Give her nitroglycerin sublingual and order a

treadmill stress test– Refer for emergent angiography– Order nuclear perfusion imaging– Start ASA, BB, nitrates and monitor symptoms

Page 4: The Evaluation Of Ischemia

Case

• During a treadmill stress test she exercises for 6 minutes and stops for chest discomfort. There are infer-lateral ST depressions and nuclear imaging shows a moderate sized reversible inferior defect and no fixed defects. Which of the following is true?– An angiogram followed by a stent will improve her

symptoms– An angiogram follow by a stent with improve her

symptoms and prolong her life– The patient should be sent for a CABG – The patients medical therapy is not optimized

Page 5: The Evaluation Of Ischemia

CAD And Angina: Significant Morbidity and Mortality

• Incidence 213/100,000 over 30• Lifetime risk: nearly 50% men, 32% women• 13,200,000 with CAD, 6,500,000 with angina• 7,200,000 post MI• 53% of cardiovascular deaths• About 1 in 5 deaths in Americans• 142.5 billion in 2006• 11.1 million deaths worldwide by 2020

Libby. Braunwald’s Heart Disease. 8th Ed.

Page 6: The Evaluation Of Ischemia

Cumulative Risk Of CAD Remains High In Advanced Age

Lloyd-Jones. Lancet, 1999.

Page 7: The Evaluation Of Ischemia

Angina• Chest or surrounding area caused by ischemia• Brought on by exertion• No associated with myocardial necrosis• Variety of discomfort

– Heavy, squeezing, pressure numb burning• Location

– Substernal, arms, epigastric• Anginal equivalents

– Dyspnea, faintness, fatigue• Duration

– Better with rest or nitroglycerin

Page 8: The Evaluation Of Ischemia

Not Angina

• Pleuritic pain• Highly localized pain• Reproduced by movement• Duration very long or very short• Pain radiating to the lower extremities• Resolution more than 5-10 minutes after

nitrates or rest

Page 9: The Evaluation Of Ischemia

Features That Decrease The Liklihood Of Chest Pain Being Angina

Panju. JAMA, 1998.

Page 10: The Evaluation Of Ischemia

Grading Angina

• Class I: angina with strenuous activity• Class II: Slight limitation of ordinary activity• Class III: Marked limitation of ordinary activity• Class IV: Inability to do any physical activity or

angina at rest

Goldman. Circulation, 1981.

Page 11: The Evaluation Of Ischemia

If It Is Not From The Heart….

Panju. JAMA, 1998.

Page 12: The Evaluation Of Ischemia

Pathophysiology

• Regional myocardial ischemia– Inadequate coronary blood flow– Increased myocardial oxygen demand

Page 13: The Evaluation Of Ischemia

Pathology of Atherosclerosis

Abrams. NEJM, 2005.

Page 14: The Evaluation Of Ischemia

Factors Influencing Myocardial Oxygen Supply and Demand

Libby. Braunwalds Heart Diseasea. 8th Ed.

Page 15: The Evaluation Of Ischemia

Cardiovascular Risk Assessment

• Very high risk: no further estimation– Established vascular disease

• Prior MI = 5-7x risk of recurrent MI• Prior stroke= 2-3x risk of MI• PVD = 4x risk of MI

– Diabetes– Chronic kidney disease– Hereditary dislipidemia

Canto. JAMA, 2003.

Page 16: The Evaluation Of Ischemia

Risk of MI In Diabetics With No History of CAD

Haffner. NEJM, 1998.

Page 17: The Evaluation Of Ischemia

Why Assess Risk?

• Required for determination of medical management

• More than 90% of CHD events in patients with at least one risk factor

Page 18: The Evaluation Of Ischemia

Risk Factors Associated With CAD

Yusuf. Lancet, 2004.

Page 19: The Evaluation Of Ischemia

Framingham Risk Calculator

• Predicts risk of MI, CAD death and angina– Low risk <10% risk in 10 years– Intermediate 10-20% risk in 10 years– High risk >20% in 10 years

Page 20: The Evaluation Of Ischemia

Risk Assessment Tools: Framingham Risk Calculator

Page 21: The Evaluation Of Ischemia

Other Risk Calculators

• SCORE• QRISK/QRISK 2• Reynolds

Page 22: The Evaluation Of Ischemia

Limitations Of Risk Calculation

• Falsely reassure patients with borderline risk factors

• Does not consider lifetime risk• Inability to account for effects of current

therapy• Variation in severity of first event• Variation by type of vascular disease

Page 23: The Evaluation Of Ischemia

High Sensitivity CRP: Additive Value?

• Most patients with CAD have traditional risk factors

• Unclear that CRP adds value in clinical practice to traditional risk factors

Page 24: The Evaluation Of Ischemia

Evaluation of Anginal Chest Pain

• Risk factor assessment• Physical Examination• Resting electrocardiogram

Page 25: The Evaluation Of Ischemia

Asymptomatic Patients

• No need for stress testing

Page 26: The Evaluation Of Ischemia

Non Invasive Stress Testing In Symptomatic Patients

• Not useful for diagnosis of CAD in low risk or high risk patients

• Useful if it will alter the planned management strategy

Page 27: The Evaluation Of Ischemia

Treadmill Stress Testing

• Useful in patients who can:– Exercise on the treadmill adequately– Have a interpretable EKG

Page 28: The Evaluation Of Ischemia

Echo Stress Testing

• Can be performed with exercise or with dobutamine

• Requires adequate echo visualization of the heart

Page 29: The Evaluation Of Ischemia

Nuclear Stress Testing

• Can be performed with exercise vasodilator drugs– Adenosine– Dipyridamole

• Nuclear tracer is distributed in areas with normal blood flow

• Requires contrast between areas of the heart– False negatives with global ischemia

Page 30: The Evaluation Of Ischemia

Sensitivity And Specificity Of Stress Testing

ModalityTotal

PatientsSensitivity

[†]

Specificity[†]

Exercise ECG 24,047 0.68 0.77

Exercise SPECT 5,272 0.88 0.72

Adenosine SPECT 2,137 0.90 0.82

Exercise echocardiography

2,788 0.85 0.81

Dobutamine echocardiography

2,582 0.81 0.79

Gibbons. JACC, 2002.

Page 31: The Evaluation Of Ischemia

High Risk Stress Test Features: Proceed to Angiography

Gibbons. JACC, 2002.

Page 32: The Evaluation Of Ischemia

Moderate And Low Risk Exercise Testing

Gibbons. JACC, 2002.

Page 33: The Evaluation Of Ischemia

CT Coronary Angiography

• Sensitity 90%• Specificity 50%• Not recommended for clinical use

Page 34: The Evaluation Of Ischemia

Coronary Angiography

• Gold standard for identification of significant CAD• Potential for revascularization• Cannot predict future site of plaque rupture and MI• Indications

– Concern for left main or triple vessel disease– Poorly controlled symptoms– Ischemia at a low workload (5-6 mets)– Large or multiple defects or WMA

Page 35: The Evaluation Of Ischemia

Assessment of Left Ventricular Function

• Echocardiography or nuclear study• Necessary for strategizing the approach to

management

Page 36: The Evaluation Of Ischemia

Treat Medical Conditions That Can Worsen Ischemia

• Anemia• Weight gain• Thyroid disease• Fever • Infections• Tachycardia• Cocaine

Page 37: The Evaluation Of Ischemia

Necessary Lifestyle Modification

• Diet • Exercise• Work activities• Leisure activities

– Avoidance of sudden exertion or isometric exercise

• Sexual activity– If equivalent level of activity is well tolerated– Sildenafil cannot be taken with nitrates

Page 38: The Evaluation Of Ischemia

Hypertension Management

• For adults, the risk of CAD double for every increase of 20 mmHg over SBP 115

• Predisposes to vascular injury, accelerates CAD, increases myocardial O2 demand and worsens ischemia

• Goals of treatment– Less than 140/90 or– Less than 130/80 in DM or CKD

Page 39: The Evaluation Of Ischemia

Smoking Cessation Decreases MI Risk

• Meta analysis of 20 studies

• 30% reduction in risk of recurrent event in patients who quit smoking

• The most effective and least expensive approach

Critchley. JAMA, 2003.

Page 40: The Evaluation Of Ischemia

Goals Of Medical Management In Stable CAD

• Improve mortality and morbidity • Manage symptoms

– Improve treadmill performance and time to ST changes

• Prevent progression of atherosclerotic disease• Requires adequate dosing and combination

approach

Page 41: The Evaluation Of Ischemia

Aspirin

• Myocardial infarction reduction of 34-87%• No difference in 81 vs 325 mg dose • Clopidogrel may substitute for aspirin in

intolerant patients

Page 42: The Evaluation Of Ischemia

Nitrates

Chen. Proc Natl Acad Sci, 2002.

• Nitrates– Systemic vasodilator -> reduced LV wall stress– Reduced myocardial oxygen demand – Acute or chronic treatment– Tolerance can

develop– Improved ex

tolerance, time to angina, and ST changes

Page 43: The Evaluation Of Ischemia

Beta Blockers• Beta receptors

– B1: increase HR, contractility, AV conduction

• cardioselective– B2: vasodilation and

bronchodilation– B3: catecholamine induced

thermogenesis• Reduction in myocardial

oxygen demand– Heart rate, contractility and wall

stress• Improved mortality

– Prior MI or heart failure

Page 44: The Evaluation Of Ischemia

ACE Inhibitors

• No benefit in the reduction of ischemia

• Benefits shown in patients with CAD and normal LV function

• Improve endothelial functioning

• HOPE Trial and EUROPA– 20-22% RR ischemic event

HOPE Investigators. NEJM, 2000.

Page 45: The Evaluation Of Ischemia

Cholesterol Lowering Improves Mortality

NCEP. NHLBI, 2003.

Page 46: The Evaluation Of Ischemia

Number Needed To Treat Is Low

NCEP. NHLBI, 2003.

Page 47: The Evaluation Of Ischemia

LDL Target Based On Presence of Risk Factors

Page 48: The Evaluation Of Ischemia

After Reaching LDL Goals, Target Non-HDL Cholesterol, Then HDL

• Total cholesterol – HDL= LDL + VLDL• 30 mg/dl higher than LDL goal• Treatment

– Statin followed by niacin or fibrates• Low HDL: <40• Treatment

– Lifestyle modification– Niacin or fibrates

Page 49: The Evaluation Of Ischemia

Ranolazine: Novel Antianginal

• No significant changes in heart rate or blood pressure• Reduction in calcium overload via inhibition of the

late Na current• Improved exercise performance and time to ischemia• Slight prolongation of the the QT interval, but no

association with TDP• Contraindicated in pre-existing QT prolongation

Page 50: The Evaluation Of Ischemia

Revascularization

• CABG or PCI• No evidence for mortality reduction in

patients with stable angina and normal LV function

Page 51: The Evaluation Of Ischemia

Courage Trial: Initial Medical Management vs PCI

• Unclear benefit of PCI in stable CAD• Inclusion criteria

– At least one70% proximal stenosis, and objective ischemia– At least one 80% stenosis and classic angina

• Exclusion criteria– Persistent CCS class IV angina– Markedly positive stress test– Refractory heart failure or cardiogenic shock– EF < 30%– Revascularization within 6 months– Anatomy unfavorable to PCI

• Randomized 1149-> PCI, 1138-> medical management• Endpoints

– Death and nonfatal MI– Death, MI, stroke or unstable angina

Page 52: The Evaluation Of Ischemia

Courage Trial: No Difference Between Initial PCI And Medical Management

Boden. NEJM, 2007.


Recommended